Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Shlaes

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|January 30, 2010
The pleuromutilin antibiotics: a new class for human useRodger Novak, David M Shlaes
Antimicrobial Agents and Chemotherapy|December 25, 2014
Reply to "Simple solutions reflect misunderstanding of animal antibiotic use"Matthew Metz, David M Shlaes
Current Opinion in Pharmacology|July 27, 2012
Overcoming the challenges to developing new antibioticsDavid M Shlaes, Brad Spellberg
Pathogens & Immunity|April 18, 2019
Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about itDavid M Shlaes, Patricia A Bradford
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
The United States Food and Drug Administration and the end of antibioticsDavid M Shlaes, Robert C Moellering
The Lancet. Infectious Diseases|January 29, 2008
Telithromycin and the FDA: implications for the futureDavid M Shlaes, Robert C Moellering
Antimicrobial Agents and Chemotherapy|July 31, 2013
The FDA reboot of antibiotic developmentDavid M Shlaes, Dan Sahm, Carol Opiela, et al.
Biochimica Et Biophysica Acta|May 3, 2003
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureusAlexey Ruzin, Anatoly Severin, Soraya L Moghazeh, et al.
Journal of Bacteriology|March 27, 2002
Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reactionAlexey Ruzin, Anatoly Severin, Frank Ritacco, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2004
Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteriaAlexey Ruzin, Guy Singh, Anatoly Severin, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Current Opinion in Investigational Drugs (London, England : 2000)|January 30, 2010
The pleuromutilin antibiotics: a new class for human useRodger Novak, David M Shlaes
Antimicrobial Agents and Chemotherapy|December 25, 2014
Reply to "Simple solutions reflect misunderstanding of animal antibiotic use"Matthew Metz, David M Shlaes
Current Opinion in Pharmacology|July 27, 2012
Overcoming the challenges to developing new antibioticsDavid M Shlaes, Brad Spellberg
Pathogens & Immunity|April 18, 2019
Antibiotics-From There to Where?: How the antibiotic miracle is threatened by resistance and a broken market and what we can do about itDavid M Shlaes, Patricia A Bradford
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
The United States Food and Drug Administration and the end of antibioticsDavid M Shlaes, Robert C Moellering
The Lancet. Infectious Diseases|January 29, 2008
Telithromycin and the FDA: implications for the futureDavid M Shlaes, Robert C Moellering
Antimicrobial Agents and Chemotherapy|July 31, 2013
The FDA reboot of antibiotic developmentDavid M Shlaes, Dan Sahm, Carol Opiela, et al.
Biochimica Et Biophysica Acta|May 3, 2003
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureusAlexey Ruzin, Anatoly Severin, Soraya L Moghazeh, et al.
Journal of Bacteriology|March 27, 2002
Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reactionAlexey Ruzin, Anatoly Severin, Frank Ritacco, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2004
Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteriaAlexey Ruzin, Guy Singh, Anatoly Severin, et al.
Pageof 3